E87: Emerging markets, Sri Lanka, 9.1% CPI, market sentiment, NASA's Webb telescope & more
2022-07-14 spoken.md · speaker-labeled ▶ watch ← E86 all episodes E88 →
Every number here is replayed from score_events — the same ledger the pool ranks on. Decay is what the 77 ideas nobody mentioned gave up this week; it applies only when an episode is processed.
Tier crossings
conviction thresholds crossed by this episode — 65 / 45 / 15 · ideas born here show where they landed. why 65 isn't always green
Kill dates that landed since E86
2 hit · 0 partial · 2 miss — windows that closed after 2022-07-08 and up to 2022-07-14, auto-scored against price data and never hand-set. verdict · R · α
| idea | verdict | R | α | closed |
|---|---|---|---|---|
| 📈 California / San Francisco governance decline drives an exodus | HIT | +44.6% | +54.1 | 2022-07-09 |
| ⚡ Distributed backup power boom — generators and rooftop solar | MISS | -47.2% | -37.7 | 2022-07-09 |
| 🛢️ Global drought turns self-sufficient countries into food importers | HIT | +15.1% | +24.6 | 2022-07-09 |
| 🛢️ Western water scarcity repriced water rights and infrastructure | MISS | -13.2% | -3.7 | 2022-07-09 |
Who moved the board
each voice's force on conviction this episode — supports and opposes, weighted exactly as the replay applied them · share = % of this episode's movement
What got argued (14 ideas)
ordered by how hard each idea moved · quotes are verbatim from the transcript, timestamps deep-link into the episode
June's 9.1% CPI is not the top: lagging owners'-equivalent rent keeps prints in the nines even as oil rolls over, so the Fed has to keep going. The true equilibrium (Taylor) rate is nearer 5% than the 3% the curve prices, so rates overshoot market expectations and that repricing is a downside surprise for both bonds and equities.
Chamath wrote a $125M check into a ~$500M round (alongside Royalty Pharma founder Pablo Legorreta and Carlos Slim) for ProKidney, which harvests a patient's own kidney cells, amplifies selected cell lines and re-injects them to lift eGFR in chronic kidney disease and dialysis patients. The bet is that the clinical data advances and the just-listed company reprices on it.
As a result, a lot of dollars are moving out of emerging market debt into US debt, and the price of that debt has collapsed. We've seen in the last couple of months a decline of emerging market debt of about 20 percent. This makes it harder for those countries to issue new debt to fund things, and it's creating this really challenging spiral that may ultimately lead to defaults.
And I'm going to still maintain that the E is wrong. The earnings are wrong for most of these companies. So why? Well, one is that when these companies start to report their quarterly earnings starting in the next few days, the year-over-year comparison is going to be to the numbers that they posted in Q2 of 2021, which by all accounts was a blowout number.
It feels like things are turning over in real estate. We talked about that last week. The number of homes being listed is skyrocketing. The number of mortgages being originated is plummeting while the rate goes up. So we're going to see mortgage rates probably go six, seven percent towards the end of the year.
So they don't necessarily have to buy at any point. They just need to make money in the end. So right now we're in a situation where the markets are looking for a direction. Retail seems to think that direction should be up. Hedge funds don't have an opinion or saying, we're just going to wait this thing out.
We're investing, but we see that the pace of deal making has slowed way down because founders know that valuations have gone down, the fundraising environment is tougher. So last year, they're raising every nine months. Now they know they should probably be raising it once every two years.
Episode digest
written during extraction and stored in data/extractions/ep087.json — the auditable source of truth, including everything market-adjacent that did not earn a capture
Taped the day the 9.1% June CPI print landed, and both Chamath and Sacks called the top a fake-out: Sacks explicitly walked back his own April/May 'inflation has peaked' call ('the lapping effect turned out not to be enough'), and Chamath argued the true equilibrium rate is nearer 5% than the 3% the market prices - a new idea, since the market's shrug at the print was the whole debate. The bigger reversal is Chamath's: the proposer of the eighth-inning tech-bottom call now says hedge funds are on the sidelines, don't have to buy at any point, and it's retail carrying the flows - the exact opposite of his own 'cash on the sidelines buys the bottom within weeks' mechanism, while Friedberg took the other side and said allocators start deploying this quarter. The A-block was a full-hour emerging-market debt spiral (Friedberg: EM debt down 20%, a spiral 'that may ultimately lead to defaults'; Chamath: 19 sovereigns at distress levels, 'as goes Sri Lanka, so goes Ghana, so goes Pakistan'), and Sri Lanka's ESG-driven fertilizer ban reinforced both the crop-shortfall and the green-policy-reversal theses. Chamath disclosed a $125M personal check into ProKidney (PROK, de-SPAC'd two days earlier), and Sacks made a dated call that the Western Alliance fractures this winter. Diarization is CLEAN - turn counts normal with Jason top talker, all four addressed-by-name tests pass, and fingerprints check out (Chamath's Sri Lankan descent and Opendoor/SoFi underwriting, Sacks' Craft deal pace, Friedberg's Webb science corner).